… , dabigatran vs apixaban, and rivaroxaban vs apixaban were performed following … relative
effectiveness and safety of dabigatran vs VKA among the PS-trimmed and PS-matched patient …

… , Antwerp, Belgium; 6Faculty of Medicine and Life Sciences, Hasselt University, Hasselt,
Belgium; 7Department of Neurology, Universitätsklinikum Würzburg, Würzburg, Germany; …

… for apixaban (only 18 studies comparing apixaban with VKAs … for apixaban in comparison to
rivaroxaban and dabigatran. … use of NOACs in routine daily practice, confirming RCT findings…

… study was to describe NVAF patients treated with apixaban compared with conventional
VKA in terms of bleeding, stroke and systemic embolic events in daily clinical practice in Spain. …

… After the launch of DOACs, several comparative effectiveness studies have been conducted
… of how routine oral anticoagulation is delivered in clinical practice and supplements data …

… demonstrated better efficacy and safety characteristics than … effects of using apixaban instead
of VKA in the German NVAF … in clinical practice with an overall prevalence of around 2% …

… composite DOACs and apixaban (number needed to treat, NNT 101 … in Germany: dabigatran,
rivaroxaban, apixaban and … to decisions in daily clinical practice, several limitations hold …

… Germany has steadily increased and since 2016 exceeded the number of previously preferred
vitamin K antagonists … observable, as dabigatran and apixaban user show a higher stroke …

… initiators; apixaban and warfarin patients were also more likely … of anticoagulants in routine
clinical practice. Other strengths … cohorts for comparative effectiveness assessment across the …

… safety or efficacy were observed between apixaban 2.5 mg BID and vitamin K antagonists in
patients with atrial fibrillation … in Germany, randomized comparison of a standardized NOAC …